Position in CRMD
as of Mar 31, 2026
· filed Jun 18, 2026
Position Value
$3,942,409
+$989,599 QoQ
Shares Held
580,620
+128.7% QoQ
Ownership
0.740%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in CRMD Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Pacer Advisors, Inc. holds $745,075,920 across 25 Biotechnology names. CRMD ranks #12 (0.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
358,633 | $277,094,201 | |
| 2 | INCY |
Incyte Corp
|
1,741,061 | $163,868,661 | |
| 3 | JAZZ |
Jazz Pharmaceuticals plc
|
503,013 | $95,094,607 | |
| 4 | EXEL |
Exelixis, Inc.
|
1,549,611 | $66,462,815 | |
| 5 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
88,863 | $39,680,884 | |
| 6 | RPRX |
Royalty Pharma plc
|
689,194 | $33,060,636 | |
| 7 | HALO |
Halozyme Therapeutics, Inc.
|
295,524 | $19,099,716 | |
| 8 | CPRX |
Catalyst Pharmaceuticals, Inc.
|
361,794 | $8,958,019 |
All Filings in CRMD
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $3,942,409 | 580,620 | Shares | Sole | 2026-06-18 | |
| 2025-12-31 | $2,952,810 | 253,896 | Shares | Sole | 2026-02-24 | |
| No filing history on record for this holder in this stock. | ||||||